Jan 2026 ANVISA GMP renewed for Tarapur facility Read more
Phone — pending confirmation info@naprodgroup.com
Partner With Us

Capabilities / Research & Development

A pipeline tracked by molecule, not by adjective.

Naprod's Formulation & Development and Analytical Development functions (F&D/ADL) carry 24 named products through development today — oncology injectables, critical-care and anesthesia injectables, and oncology oral solid dosage — each one assigned a dossier-status milestone rather than a marketing claim.

24 products under development across 3 pipeline areas, tracked to named dossier-status dates from Under Feasibility & Evaluation through Under Development 2026–2028.

View the marketed catalog Talk to us about a molecule

How the pipeline moves

Three stages, one register

Every molecule in the F&D/ADL pipeline sits in one of three stages, tracked against a dated milestone rather than a general timeline. Feasibility & Evaluation — pre-formulation screening and route selection, before a formal development timeline is set. In Development — active formulation, process and analytical method work against a named dossier-status date (quarter or year). Under R&D — longer-horizon molecules on a multi-year development arc. As of this page's last data refresh, the register carries 15 products In Development, 7 in Feasibility & Evaluation, and 2 Under R&D — 24 in total.

  • 15

    In development

  • 7

    Feasibility & evaluation

  • 2

    Under R&D

  • 24

    Total pipeline products

Pipeline area 1 of 3

Oncology injectables — RTU and standard formats

Four oncology injectable molecules are in active development, split across ready-to-use (RTU) and standard injection formats. Oxaliplatin RTU Injection (5mg/ml) and Pemetrexed RTU Injection (25mg/ml) are both tracked to Under Development 2026. Zoledronic Acid Injection (4mg/5ml) is tracked to Under Development 2026, and Azacitidine Injection (100mg) is tracked to Q4 2026. All four build directly on Naprod's existing lyophilized and liquid oncology injectable manufacturing base at Tarapur.

Pipeline area 2 of 3

Critical-care and anesthesia injectables

The largest single group in the pipeline: eight critical-care, anesthesia and anti-infective injectables, all In Development. Rocuronium Bromide Injection (10mg/ml) and Labetalol Injection (5mg/ml) are tracked to Q2 2026. Etomidate Injection (20mg/10ml), Dalbavancin Injection (500mg) and Daptomycin Injection (500mg) are tracked to Under Development 2026. Olanzapine Injection (10mg) is tracked to Under Development Q2 2026. Parecoxib Injection (40mg) is tracked to Under Development 2026, and Dexmedetomidine Injection (200mcg/2ml) is tracked to Under Development 2026 — this last molecule appears in the company's development register under the transcribed spelling "Dexmedetomitidine"; standard nomenclature is Dexmedetomidine.

Pipeline area 3 of 3

Oncology oral solid dosage — the largest expansion

Twelve oncology tablets and capsules make up half the pipeline — Naprod's stated move from an injectables-only oncology base into oral oncology. Furthest along: Palbociclib Tablet (75mg/100mg/125mg) and Enzalutamide Tablet (40mg/80mg), both tracked to Under Development / End of 2026, and Ibrutinib Tablet (140mg/280mg/420mg/560mg), tracked to Under Development / End of 2027. Lenvatinib Capsule (4mg/10mg) is tracked to Under R&D 2027 and Nilotinib Capsule (150mg/200mg) to Under R&D 2028. Seven further molecules sit in Feasibility & Evaluation ahead of a formal development date: Carbozantinib Tablet (20mg/40mg/60mg — company register spelling; standard nomenclature is Cabozantinib), Ribociclib Tablet (200mg), Abemaciclib Tablet (100mg/150mg), Anlotinib Hydrochloride Capsule (8mg/10mg/12mg), Tucatinib Tablet (150mg), Upadacitinib Tablet (15mg/30mg), and Olaparib Tablet (150mg).

Why this matters to a regulatory or sourcing team

Development against the same quality system as commercial supply

Pipeline molecules move through the same Tarapur, Maharashtra site that holds Naprod's current EU-GMP, WHO-GMP, ANVISA (Brazil, renewed Jan 2026), INVIMA (Colombia), UAE Ministry of Health and NHRA (Bahrain) certifications — see the Quality & Regulatory register for scope and validity dates. That means a dossier moving out of Feasibility & Evaluation inherits an already-audited manufacturing base rather than starting quality infrastructure from zero.